reduce basal insulin when starting glp-1 receptor agonist GLP-1-based therapies for type 2 diabetes: from single, dual and triple agonists to endogenous production and L-cell differentiation | Diabetology & Metabolic Syndrome Adding a GLP-1 receptor agonist
Description
As governments and insurers recognize the economic and healthcare burden of obesity, coverage and accessibility are set to improve, further accelerating market adoption
Sutapa Ghosh
2017;5 doi: 10.14814/phy2.13073
There is a randomized controlled phase 2 study with the objective to explore the use of TZP as a treatment for MAFLD, providing strong evidence [NCT04166773]
Indeed, at their peak in 2024, nearly 1 in 3 Americans taking a GLP-1 drug said they were getting it from a compounding pharmacy
10.1146/annurev-immunol-042617-053010 Annu
